Puyuan Xing - Concepedia

Author

Puyuan Xing

Chinese Academy of Medical Sciences & Peking Union Medical College ORCID

Also Known As

P Xing, P Y Xing, P. Xing, PUYUAN XING, Peinong Xing, Peixin Xing, Pu-Yuan Xing, Pu-yuan Xing, Puyuan Xing, Pu‐Yuan Xing

282

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

Chinese Academy of Medical Sciences & Peking Union Medical College Peking Union Medical College Hospital Peking University Anhui Medical University Shandong First Medical University

About

Puyuan Xing is an author at Chinese Academy of Medical Sciences & Peking Union Medical College specializing in oncology, medicine, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	15	766
2	Health Sciences	4	4	94
3	Cell Biology	3	3	191
4	Public Health	1	1	132
5	Global Health	1	1	132

Puyuan Xing

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Fei Ma, Qiao Li, Shanshan Chen, Journal of Clinical Oncology Metastatic Breast CancerOncologyBiomarker AnalysisPyrotinib ExposureBreast Oncology	2017	228
Clinical characteristics and medical service utilization of lung cancer in China, 2005–2014: Overall design and results from a multicenter retrospective epidemiologic survey Jufang Shi, Le Wang, Ning Wu, Lung Cancer Medical Service UtilizationOncologyCancer EpidemiologyGlobal HealthClinical Characteristics	2018	132
Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial Qiao Li, Xiuwen Guan, Shanshan Chen, Clinical Cancer Research	2019	89
A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy Jing Huang, Yi Zhou, Hong‐Tu Zhang, Medical Oncology Esophageal CancerMedicineBiweekly PaclitaxelPathologyErcc1 Expression	2012	79
What are the clinical symptoms and physical signs for non‐small cell lung cancer before diagnosis is made? A nation‐wide multicenter 10‐year retrospective study in China Puyuan Xing, Yixiang Zhu, Le Wang, Cancer Medicine	2019	75
Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes Yuxin Mu, Xuezhi Hao, Puyuan Xing, Journal of Cancer Research and Clinical Oncology	2020	63
Response to crizotinib in advanced ALK -rearranged non-small cell lung cancers with different ALK -fusion variants Yan Li, Tongtong Zhang, Jing Zhang, Lung Cancer OncologyMedicinePathologyBronchial NeoplasmAdvanced Alk	2018	61
Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3) Yuankai Shi, Lin Wu, Xinmin Yu, Cancer Communications	2022	53
Betulinic acid exerts potent antitumor effects on paclitaxel‑resistant human lung carcinoma cells (H460) via G2/M phase cell cycle arrest and induction of mitochondrial apoptosis Xiaokai Zhan, Junling Li, Sen Zhang, Oncology Letters Chemoprevention StrategyApoptosisCell DeathTumor BiologyCancer Cell Biology	2018	51
Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I–III Lung Adenocarcinoma Xiaohong Han, Qiaoyun Tan, Sheng Yang, Frontiers in Oncology	2019	45

Page 1